Welcome!

News Feed Item

Resmed Inc. Announces Record Financial Results For The Quarter Ended And Nine Months Ended March 31, 2014

SAN DIEGO, April 23, 2014 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended March 31, 2014.  Revenue for the quarter was $397.8 million, a 4 percent increase (a 3 percent increase on a constant currency basis) over the quarter ended March 31, 2013.  Net income was $90.0 million, an increase of 6 percent compared to the quarter ended March 31, 2013.  Diluted earnings per share for the quarter were $0.63, an increase of 9 percent compared to the quarter ended March 31, 2013.  

ResMed Inc. logo

Selling, general and administrative expenses were $115.1 million for the quarter, an increase of 5 percent (a 7 percent increase on a constant currency basis) over the quarter ended March 31, 2013.  SG&A costs were 28.9 percent of revenue in the quarter, compared to 28.6 percent in the quarter ended March 31, 2013.    

Research and development expenses were $29.5 million for the quarter, or 7.4 percent of revenue.  R&D expenses decreased by 5 percent (a 7 percent increase on a constant currency basis) compared to the quarter ended March 31, 2013.  R&D expenses were favorably impacted by the depreciation of the Australian dollar against the U.S. dollar.

ResMed amortized acquired intangibles of $2.5 million ($1.9 million, net of tax) during the quarter.  Stock-based compensation costs incurred during the quarter of $11.2 million ($8.1 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and the company's employee stock purchase plan.  

For the nine months ended March 31, 2014, revenue was $1,139.8 million, an increase of 4 percent over the nine months ended March 31, 2013 (a 3 percent increase on a constant currency basis).  For the nine months, net income was $257.5 million, an increase of 10 percent compared to the nine months ended March 31, 2013.  Diluted earnings per share for the nine months were $1.78 per diluted share, an increase of 11 percent compared to the nine months ended March 31, 2013.

In the third quarter of fiscal year 2014, revenue outside the Americas was $181.6 million, an increase of 8 percent over the prior year's quarter.  In constant currency terms, revenue outside the Americas increased by 6 percent. Revenue in the Americas, at $216.1 million, remained flat compared to the prior year's quarter of $215.2 million. Operating profit for the third quarter grew to $104.7 million, cash flow from operations was $101.1 million, while gross margin was 63.3 percent, all demonstrating robust operating performance. During the quarter, the company also repurchased 1.6 million shares at a cost of $72.5 million, as part of its ongoing capital management program.

"We are pleased with our third quarter results in the face of challenging market conditions, particularly in the U.S.," said ResMed chief executive officer Michael "Mick" Farrell.  "Our Americas business showed encouraging trends and we continue to benefit from our globally diversified business, with constant currency revenue growth of 6 percent in combined Europe and Asia-Pacific businesses for the quarter. In particular, our European results were strong across the board, with most countries showing solid growth."

Highlighting ResMed's new products, Farrell continued, "At the beginning of the third quarter, we launched our new nasal pillows interface, the AirFitP10, in the U.S., and it's been very well received. In addition to its brisk adoption, we received global validation of our innovation and design excellence when the AirFit P10 won the prestigious 2014 Red Dot Product Design award, the world's largest design competition. Sales of the AirFit P10 have just begun in Europe and Asia-Pacific.  Earlier this week, ResMed announced the U.S. launch of two additional new masks to kick-start the fourth quarter of its fiscal year: the AirFit F10, the lightest full-face mask on the market; and the AirFit N10, a new patient-preferred nasal mask. Both masks will be launched soon in other major countries.

"On the flow generator side, we are now in the full product launch phase of our new respiratory care platform in Europe.  The Astral™ is our new generation of life support ventilators. Its competitive advantages are its small size and long battery life, making it an ultra-portable system. It showcases ResMed's growing strength in software design, with patient-friendly set-up and operation. These features allow adult and pediatric patients, who would otherwise be hospitalized, to be safely treated outside the hospital for various chronic diseases. The Astral platform also won a prestigious Red Dot Product Design award, and received positive reaction from patients, providers, and physicians during its controlled product launch in Europe during the third quarter.  We are now ready for full commercial launch of this respiratory care platform in Europe and Asia-Pacific, and our U.S. launch is pending FDA clearance, which we anticipate later this year," Farrell said.

Farrell concluded, "We were also particularly pleased with our bottom-line results this quarter.  Our operating profit, net income, and earnings per share all grew year-over-year at a faster pace than our revenue, with earnings per share up 9 percent.  We expect to continue to take advantage of ongoing growth opportunities in sleep-disordered breathing, chronic obstructive pulmonary disease, and cardiorespiratory diseases.  Our offerings improve patient outcomes and quality of life, while reducing costs for global healthcare systems."

The ResMed board of directors has today declared a quarterly dividend of $0.25 per share, which will have a record date of May 20, 2014, and be payable on June 17, 2014. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares.  Because the two exchanges have different settlement and transfer procedures, the ex-dividend periods before the record date will be different for common stock and for CDIs. The ex-dividend date will be May 14, 2014 for CDI holders and May 16, 2014 for common stock holders. As a result of these differences, ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 14, 2014 through May 20, 2014, inclusive. 

About ResMed

ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 1:30 p.m. U.S. Pacific Time today to discuss these quarterly results.  Individuals wishing to access the conference call may do so via ResMed's website at www.resmed.com or by dialing 847-585-4405 (domestic) or +1 847-585-4405 (international) and entering conference passcode no. 36956405.   Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player), required to listen to the internet broadcast.  The online archive of the broadcast will be available approximately 30 minutes after the live call and will be available for two weeks.  A telephone replay of the conference call is available by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering conference I.D. No. 36956405.

For Investors: Further information can be obtained by contacting David Pendarvis at ResMed Inc., San Diego, at (858) 836-5000; Brett Sandercock at ResMed Limited, Sydney, at (+612) 8884-2090; or by visiting the company's multilingual website at www.resmed.com

For News Media: Contact Gretchen Griswold, director of Global Corporate Communications at (858) 836-6789.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements -- including statements regarding ResMed's projections of future revenue or earnings,  expenses, new product development, new product launches and new markets for its products --  are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission.  ResMed does not undertake to update its forward-looking statements.

 

ResMed Inc and Subsidiaries

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)



Three Months Ended

March 31,

Nine months Ended

March 31,


2014

2013

2014

2013






Net revenue

$397,758

$383,581

$1,139,762

$1,099,850

Cost of sales

145,970

144,132

411,234

419,041

Gross profit

251,788

239,449

728,528

680,809






Operating expenses:





Selling, general and administrative

115,101

109,628

328,172

315,745

Research and development

29,530

31,189

86,430

88,735

Amortization of acquired intangible assets

2,459

2,533

7,325

7,671

Total operating expenses

147,090

143,350

421,927

412,151

Income from operations

104,698

96,099

306,601

268,658






Other income (expenses), net:





Interest income (expense), net

6,015

8,078

19,182

25,047

Other, net

2,199

3,815

(1,340)

3,587

Total other income (expenses), net

8,214

11,893

17,842

28,634






Income before income taxes

112,912

107,992

324,443

297,292

Income taxes

22,943

23,079

66,908

63,172

Net income

$89,969

$84,913

$257,535

$234,120






Basic earnings per share

$0.64

$0.59

$1.82

$1.64

Diluted earnings per share

$0.63

$0.58

$1.78

$1.60






Basic shares outstanding

140,959

143,293

141,774

143,049

Diluted shares outstanding

143,375

146,643

144,758

146,479






 


ResMed Inc And Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited - In thousands)



March 31,

June 30,


2014

2013

Assets



Current assets:



Cash and cash equivalents

$938,563

$876,048

Accounts receivable, net

337,572

318,349

Inventories

164,888

145,847

Prepayments, deferred income taxes and other current assets

122,879

108,605

Total current assets

1,563,902

1,448,849

Property, plant and equipment, net

429,049

411,433

Goodwill

290,785

274,829

Other intangibles

46,153

49,639

Deferred income taxes and other non-current assets

34,677

25,971

Total non-current assets

800,664

761,872

Total assets

$2,364,566

$2,210,721

Liabilities and Stockholders' Equity



Current liabilities:



Accounts payable

$55,483

$60,688

Accrued expenses

142,082

137,674

Deferred revenue

42,182

44,953

Income taxes payable

6,353

30,090

Deferred income taxes

774

627

Current portion of long-term debt

18

300,017

Total current liabilities

246,892

574,049

Non-current liabilities:



Deferred income taxes

10,081

9,895

Deferred revenue

15,585

11,928

Income taxes payable

5,318

3,564

Non-current portion of long-term debt

395,785

769

Total non-current liabilities

426,769

26,156

Total liabilities

673,661

600,205

Stockholders' Equity:



Common stock

561

568

Additional paid-in capital

1,084,502

1,025,064

Retained earnings

1,727,789

1,576,641

Treasury stock

(1,251,482)

(1,083,845)

Accumulated other comprehensive income

129,535

92,088

Total stockholders' equity

$1,690,905

$1,610,516




Total liabilities and stockholders' equity

$2,364,566

$2,210,721




 

Logo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a

SOURCE ResMed Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Everyone wants to use containers, but monitoring containers is hard. New ephemeral architecture introduces new challenges in how monitoring tools need to monitor and visualize containers, so your team can make sense of everything. In his session at @DevOpsSummit, David Gildeh, co-founder and CEO of Outlyer, will go through the challenges and show there is light at the end of the tunnel if you use the right tools and understand what you need to be monitoring to successfully use containers in your...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the USA and Europe, we work with a variety of customers from emerging startups to Fortune 1000 companies.
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across supply chain networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost and time for product recall as well as advance trade. Are you curious about Blockchain and how it can provide you with new opportunities for innovation and growth? In her session at 20th Cloud Exp...
Cybersecurity is a critical component of software development in many industries including medical devices. However, code is not always written to be robust or secure from the unknown or the unexpected. This gap can make medical devices susceptible to cybersecurity attacks ranging from compromised personal health information to life-sustaining treatment. In his session at @ThingsExpo, Clark Fortney, Software Engineer at Battelle, will discuss how programming oversight using key methods can incre...
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
Did you know that you can develop for mainframes in Java? Or that the testing and deployment can be automated across mobile to mainframe? In his session at @DevOpsSummit at 20th Cloud Expo, Vaughn Marshall, Sr. Principal Product Owner at CA Technologies, will discuss and demo how increasingly teams are developing with agile methodologies using modern development environments and automating testing and deployments, mobile to mainframe.
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...